RLMD
Relmada Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +16.7% ·
share flow +6.7% ·
net new positions +14.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 52 | +17 | 37.42M | $258.91M | +22 | −5 |
| Q1 2026 | 36 | +1 | 37.39M | $260.09M | +3 | −2 |
| Q4 2025 | 35 | +5 | 26.87M | $129.62M | +5 | n/a |
| Q3 2025 | 8 | 0 | 1.94M | $3.90M | n/a | n/a |
| Q2 2025 | 7 | +1 | 1.68M | $1.01M | +1 | n/a |
| Q1 2025 | 4 | 0 | 703.26K | $189,901 | n/a | n/a |
| Q4 2024 | 4 | -3 | 701.66K | $364,906 | n/a | −3 |
| Q3 2024 | 6 | 0 | 1.19M | $3.85M | n/a | n/a |
| Q2 2024 | 6 | n/a | 857.82K | $2.57M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 508.00K | n/a | $304,952 | 0.0% | n/c | 1 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 364.08K | n/a | $218,446 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 302.35K | +0.2% | $181,541 | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 154.57K | New | $92,741 | 0.0% | New | 1 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 150.10K | +20.9% | $90,105 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 106.73K | 0.0% | $64,073 | 0.0% | Held | 3 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 95.42K | -44.0% | $57,279 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $92,741 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 103 holders, 83.66M shares, $576.39M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Chief Executive… · 100.00K sh @ 4.10 · $410,000
Officer · Chief Financial… · 79.80K sh @ 4.25 · $339,150
Officer, Director · Chief Executive… · 100.00K sh @ 4.18 · $418,000
Officer · Chief Financial… · 120.20K sh @ 4.20 · $504,840
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology